INTRODUCTION
Understanding the genomic alterations of disease-derived cells is of vital importance for the development of more rational diagnostics and treatment strategies. In principle, the completed sequence of the human genome allows for the interrogation of virtually every single base for variations between the canonical and disease genome sequences. However, genetic analysis of clinical samples is often limited, in practice, by the amount of genomic DNA available. New technologies allowing in vitro production of numerous copies of the entire genome are currently available. However, the extent to which such methods result in a representative copy of the initial genome and the ®delity with which such representative copies are produced remains largely uncharacterized.
Whole genome ampli®cation by multiple displacement ampli®cation is based on the use of f29 DNA polymerase and random primers (henceforth referred to as f29MDA) (1±4). f29 polymerase combines high processivity with a strand displacement ability leading to the synthesis of DNA fragments >70 kb (5) and favoring uniform representation of sequences. In addition, the enzyme possesses 3¢®5¢ exonuclease activity resulting in error rates thought to be between 10 ±5 and 10 ±6 (6) .
In this study, we have used f29MDA to amplify genomic DNA from both normal and cancer cells. We then tested the accuracy and genome-wide coverage of f29MDA through both direct sequencing of~500 000 bp of DNA and the use of high density oligonucleotide arrays interrogating >10 000 single nucleotide polymorphisms (SNPs). Genome-wide ampli®cation achieved an estimated 99.82% coverage of the human genome. SNP call concordance was comparable to that of unampli®ed replicates and, in the context of large-scale exon resequencing, highly accurate sequence data were obtained from f29MDA samples when compared to samples ampli®ed by standard methods. Finally, our ability to detect several types of chromosomal aberrations, including loss of heterozygosity (LOH), homozygous deletions and gene ampli®cation remained robust compared to non-ampli®ed samples. In summary, our results show that f29MDA affords highly accurate and comprehensive whole genome ampli®ca-tion suitable for high resolution genetic analysis.
MATERIALS AND METHODS

DNA samples
Genomic DNA samples from cell lines were obtained from ATCC (Manassas, VA). Of the 16 samples used, six were breast cancer cell/normal pairs, namely cell lines HCC1008 (renamed HCC1007 for consistency), HCC1143, HCC1599, HCC1937, HCC2218 and HCC38 and their normal counterparts generated by EBV-induced transformation of peripheral blood lymphocytes obtained from the same patients (HCC1007 BL, HCC1143 BL, HCC1599 BL, HCC1937 BL, HCC2218 BL and HCC38 BL). Samples HCC2157 BL and HCC1954 BL were unmatched. Two normal reference DNA sets from blood samples were also obtained from Affymetrix (Santa Clara, CA). For exon resequencing experiments genomic DNA from 20 samples of lung adenocarcinoma was used. DNA was quanti®ed using a PicoGreen â dsDNA quantitation kit (Molecular Probes Inc., Eugene, OR).
f29 polymerase multiple strand displacement whole genome ampli®cation
Whole genome ampli®cation reagents (REPLI-gÔ 625S; Molecular Staging Inc., New Haven, CT) were used as follows. Brie¯y, 10 ng template DNA was mixed with 4Q master mix (containing the reaction buffer and hexamer primers) and the DNA polymerase in a 50 ml ®nal volume reaction. Completed reactions were transferred to a 96-well plate and incubated for 16 h at 30°C, followed by incubation at 65°C for 3 min to inactivate the enzyme. For ®ve samples (HCC1007BL, HCC1007, HCC1143BL, HCC1143 and HCC1599BL), template DNA was denatured using alkaline denaturation prior to the f29MDA reaction (version 2 f29MDA). In all cases, 10 mg ampli®ed DNA was puri®ed using a QIAquick PCR puri®cation kit (Qiagen Inc., Valencia, CA). Puri®ed DNA was quanti®ed and 250 ng was used for SNP array analysis and 5 ng for PCR followed by sequencing.
Single nucleotide polymorphism array experiments
10K Mapping Arrays and hybridization reagents were obtained from Affymetrix (7, 8) . Aliquots of 250 ng genomic or whole genome ampli®cation DNA was restricted with XbaI. A single double-stranded linker was ligated to the XbaI fragments using T4 DNA ligase. XbaI fragments were then ampli®ed by single primer PCR as per the manufacturer's protocol. PCR products were puri®ed from free primers and nucleotides by differential precipitation in 2-propanol/sodium perchlorate. The PCR products were quanti®ed spectrophotometrically and assayed for the appropriate size distribution on a DNA analyzer (Agilent 2100 Bioanalyzer). The puri®ed PCR products were fragmented with DNase I and the resulting DNA was labeled with a single biotin at each free 3¢-OH using terminal deoxynucleotidyl transferase and a dideoxy biotinylated nucleoside triphosphate. The biotinylated fragments were added to a hybridization solution [12Q MES (1.22 M), 100% DMSO, 50Q Denhardt's solution, 0.5 M EDTA, 10 mg/ml herring sperm DNA, 3 nM Oligo B2, 1 mg/ml human Cot-1, 1% Tween-20, 5 M TMACL] containing a biotinylated control oligonucleotide (for quality control) and then hybridized to a 10K SNP microarray chip overnight at 48°C. The arrays were then washed six times with non-stringent buffer A (6Q SSPE, 0.01% Tween-20) and stringent buffer B (0.6Q SSPE, 0.01% Tween-20). Bound DNA was then detected by incubation with streptavidin followed by biotinylated anti-streptavidin, followed by phycoerythrin-conjugated streptavidin (SAPE). Bound¯uor-escent antibody was detected using a confocal laser scanner (570 nm) and the positions and intensities of the¯uorescence emissions were captured.
Single nucleotide polymorphism data visualization and analysis dChipSNP (9,10), a bioinformatics platform developed for SNP array data analysis, was used to automate the process of making LOH calls based on paired normal/tumor SNP calls and displaying the SNP data according to their chromosomal locations, along with cytogenetic band information. Figures 1B and 3B and C were generated based on`Chromosome View' in dChipSNP. The SNP call rates of unampli®ed samples were compared to those of the paired f29MDA samples using the one sample Wilcoxon rank sum test. The SNP or LOH call concordance rate between two samples was calculated as the proportion of concordant markers among all markers excluding those in which either one or both of the two samples was NO_CALL. We used the two sample Wilcoxon rank sum test to compare the SNP call concordance rate between unampli®ed samples and the two types of f29MDA samples (obtained from non-denatured and denatured DNA, respectively) to the concordance rate between unampli®ed replicates and also to compare the SNP call concordance rates between the two types of f29MDA samples. To assess the quality of f29MDA on the entire genome, all the arrays were ®rst normalized using the invariant set method and then for each SNP marker a signal intensity index was calculated using a model-based approach (11) . The fold changes in the signal intensity index between unampli®ed samples and f29MDA samples were calculated for all SNP markers and statistical signi®cance was assessed using a permutation test with multiple comparison adjustment by the maxT procedure (12) .
Copy number analysis
Based on the signal intensities, the copy number of each SNP locus in cancer cell lines samples was estimated by hidden Markov model analysis of the signal intensity variation along each chromosome, compared to a set of normal references (13) . In addition to the unampli®ed normal samples described above, over 50 additional samples from normal tissue were included as unampli®ed normal references (generously provided by E.Hochberg and J.Ritz) to improve the accuracy of copy number estimates. For the f29MDA DNA samples, f29MDA DNA obtained from immortalized lymphocytes (described above) was used as normal references. Copy number estimates were binned in the categories 0, 1, 2, 3, 4 and >4 before calculating copy number discordance rates.
PCR and sequencing
One hundred tyrosine kinase exons and¯anking intronic sequences were ampli®ed using speci®c primers in a 384-well format nested PCR set-up (J. G. Paez, J. C. Lee, M. Meverson and W. R. Sellars, in preparation). The nested primers were tagged with M13 tails. PCR was performed using 5 ng of both ampli®ed and unampli®ed DNA. PCR products were puri®ed using SPRI (solid phase reversible immobilization) chemistry followed by bidirectional dye terminator¯uorescent sequencing with universal M13 primers. Sequencing fragments were detected via capillary electrophoresis using an ABI Prism Figure 1 . Genome coverage following whole genome ampli®cation. (A) The SNP call rate before and after whole genome ampli®cation. Probes were prepared from 250 ng DNA from samples of breast cancer cell line or paired normal cell line DNA either before (unampli®ed) or after (f29MDA) ampli®cation and hybridized to Affymetrix 10K SNP arrays. In addition, 14 samples were ampli®ed without denaturation prior to whole genome ampli®cation, while ®ve samples were ampli®ed after denaturation (as indicated). (B) Regions with loss of representation after f29MDA. For each indicated region, the speci®c SNP allele hybridization intensity normalized on a scale of 0 (absent and white) to 6 (red) is shown for unampli®ed or ampli®ed samples. Each row represents a single SNP allele, while each column represents a single DNA sample. Columns 1±5 correspond to denatured DNA samples (HCC1007BL, HCC1007, HCC1143BL, HCC1143 and HCC1599BL). (C) The absence of ampli®cation of a region in the chromosome cytoband 6p25.3. Using dChip-Signal, the mean signal intensity for each SNP allele on the 10K array was compared between samples before (left) and after (right) whole genome ampli®cation. Signal intensity is shown normalized on a scale of 0 (white) to 6 (red). An enlargement of this region is shown in the middle panel. The right panel indicates the calls for each speci®c SNP allele where white is no call, yellow is AB, blue is BB and red is AA. The region indicated by the dotted line shows absent or incorrect calls in samples after MDA, corresponding to the region where signal loss was detected in dChip-Signal. Columns 1±5 correspond to denatured DNA samples. To analyze the sequencing data using the Neighborhood Quality Standard (NQS) (14, 15) , pair-wise alignments for each unampli®ed/f29MDA sample pair were generated for each amplicon and differences were detected using the NQS. Brie¯y, a base met NQS if the Phred quality (16) was b30 and the 5 bases on each side had Phred quality scores b25. Sample pairs with fewer than 50 NQS bases were discarded. In samples potentially containing deletions, average quality from neighboring bases was used as a surrogate for base quality. The number of passing sample pairs (b50 NQS bases compared) was 1585, leading to a total of 404 335 NQS bases (F&R = 1 base).
RESULTS
Genome representation after f29 polymerase-based whole genome ampli®cation
Genomic DNA from seven breast cancer cell lines and seven EBV-immortalized lymphoblastoid cell lines was used for these studies. Twelve of these samples represent six pairs comprising a cancer-derived cell line and a lymphoblastoid cell line representing the paired normal genome. Aliquots of 10 ng of each genomic DNA sample were subjected to f29MDA, yielding an average of 25 mg total DNA/sample. In addition, genomic DNA from ®ve samples was denatured by treatment with alkali prior to f29MDA. To ascertain the extent to which f29MDA resulted in whole genome representation, we determined the rate of detection for~10 000 SNPs alleles in each DNA sample, using high density oligonucleotide arrays. Here, 250 ng f29MDA DNA or unampli®ed DNA was used to prepare probes for the Affymetrix 10K SNP array. High quality array data was obtained on all samples as judged by the performance of the spiked controls. As a ®rst measure of genome representation we compared the number of SNPs successfully detected or called (the call rate) in the f29MDA samples versus unampli®ed samples by pair-wise comparison (Fig. 1A) . While all f29MDA samples performed acceptably, in samples prepared by f29MDA without a preceding denaturation step the mean call rate was 88.92%, compared to a mean of 92.45% in the unampli®ed samples. The call rate improved substantially with denaturing of genomic DNA prior to f29MDA, such that the call rates were similar between f29MDA and unampli®ed samples (92.06 versus 92.93%, P = 0.24).
We next determined whether this small decrease in the mean call rate re¯ected random loss of genomic representation differing in each f29MDA sample preparation or alternatively re¯ected non-random loss of ampli®cation of speci®c regions of the genome. Recent data from our group has shown that the oligonucleotide SNP arrays can be used not only for the robust speci®cation of allele calls, but can also detect copy number changes (13) . Thus, as a second approach to the question of genome representation after f29MDA, we normalized oligonucleotide signal intensity across all arrays using the invariant probe set method (11) and determined whether speci®c regions of the genome were under-represented in producing hybridizing fragments, as indicated by consistent loss of the hybridization signal. Here, the mean signal intensity for each SNP allele in the ampli®ed samples was compared to the mean signal intensity of the unampli®ed samples by plotting the log 2 ratio of the mean f29MDA to unampli®ed signal (as shown for chromosome 6 in Fig. 1C ). Regions of statistically signi®cant signal loss were then sought. Fourteen regions of consistent signal loss were detected in the f29MDA ampli®ed samples (Table 1) . Conversely, no regions of loss were found in unampli®ed samples when compared to the ampli®ed samples. When the speci®c SNP alleles in each region were examined in detail, six regions (1q42, 4q35, 6p25, 7q36, 10q26 and 18p11) showed both signi®cantly reduced oligonucleotide signal intensity and consistent no-call designations in the f29MDA samples (Fig. 1B and Table 1 , shaded in gray). An example of one such region located on chromosome 6p25.3 is shown in Figure 1C , where the mean signal intensity of f29MDA and unampli®ed samples, as well as the speci®c allele calls, are shown. The remaining eight regions had low signal intensity, suggesting inadequate ampli®cation, however, there was apparently suf®cient ampli®cation to allow accurate detection of the speci®c SNP alleles. The six regions of low intensity and poor SNP calls represent a maximum of 5.64 Mb (measured from the ®rst¯anking retained SNP markers). For the currently assembled human genome size of 3070 Mb (17) these data give an estimated genome coverage of (3070 ± 5.64 Mb/3070 Mb) Q 100 = 99.82%.
These regions of loss are not physically constrained to particular chromosomal segments such as telomeres, thus we examined each region to determine whether there were any obvious clues as to why such regions might be more dif®cult to amplify. While each region contains repetitive elements of the LINE, SINE and MER1 families, it is unclear whether this bears causally on the lack of ampli®cation for these small regions.
Fidelity of whole genome ampli®cation for detecting SNP alleles
In order to ascertain whether f29MDA gives robust SNP allele calls when used in a large-scale SNP genotyping application, we next determined the SNP call concordance between f29MDA ampli®ed and unampli®ed pairs. Here, only SNPs giving`calls' in both the unampli®ed and the f29MDA samples were considered. To assess the experimental variability, SNP concordance was measured in 10 pairs of replicate samples. Concordance was 99.85% among paired
replicates, 99.59% (P = 0.000004) when non-denatured f29MDA samples were compared to the unampli®ed samples and 99.80% (P = 0.12) when alkaline denatured f29MDA samples were compared to unampli®ed samples (Fig. 2A±C) .
Examination of the discrepancies between non-denatured f29MDA and unampli®ed samples showed that 63% were heterozygotes called as homozygotes. Approximately 30% of all calls were heterozygotes and hence the heterozygote dropout rate is~0.73% for this method (data not shown). It is thought that the inclusion of an alkaline denaturation step may reduce stochastic effects and serve to ensure even priming of maternal and paternal alleles. Indeed, the heterozygote dropout rate decreased by 24-fold from 0.73 to <0.03% with inclusion of the alkaline denaturation step. In no case were homozygote conversions detected.
As the rate of discordant calls found in the denatured samples was nearly identical to that found in the replicate data, we conclude that under these conditions the SNP error rate after f29MDA is within the experimental error for this assay and thus the estimated upper bound of the f29MDA error rate is <0.2%. These data indicate that highly reliable SNP genotyping can be obtained after f29MDA genome ampli®-cation.
Direct sequencing comparison
In order to test more robustly the ®delity of f29MDA, 20 samples of DNA obtained from lung adenocarcinoma were subjected to f29MDA. Next, all 20 f29MDA ampli®ed and the corresponding unampli®ed genomic DNA samples were used in nested PCR ampli®cation reactions to generate sequencing templates for 100 tyrosine kinase exons. All resulting amplicons were then used in¯uorescent dye terminator sequencing reactions with standard M13 forward and reverse primers. A total of 1295 paired f29MDA and unampli®ed sequencing reads were available for analysis by Mutation Surveyor, representing nearly 500 000 paired bases for each method. Single direction sequences where the opposite read was not available were excluded. In this dataset, variants from the canonical sequence were detected using Mutation Surveyor followed by manual review. There were 234 variants detected by both methods, four variants detected in unampli®ed samples not found in the f29MDA samples and ®ve variants found in the f29MDA samples that were not found in the unampli®ed samples (Table 2) . From these data we estimate that the error rate of PCR-based ampli®cation and sequencing is 7.6 Q 10 ±6 and that of f29MDA followed by PCR-based sequencing is 9.5 Q 10 ±6 . These error rates are not different statistically.
We also approached the question of ®delity using the NQS (14, 15) to detect homozygous changes between unampli®ed and ampli®ed samples. Because NQS excludes heterozygous base calls, it produces a lower bound on the discrepancy rate between ampli®ed and unampli®ed sample pairs. In 404 335 bases that passed the NQS quality criteria, ®ve differences were detected: four substitutions and one two-base insertion. The overall concordance rate was therefore 1 ± (5/404335) = 0.999985. In all ®ve discrepancies, the f29MDA ampli®ed sample differed from the canonical sequence. Illustrative of two of these variations are the dinucleotide insertion and the homozygous base pair substitution shown in Figure 3 . Thus a lower bound for error introduced by f29MDA estimated by NQS is 1.24 Q 10 ±5 .
These error rates are relatively low in the context of PCRbased sequencing efforts, nonetheless, the possibility of a few f29MDA-induced alterations including homozygous changes detected by the NQS method indicates that sequencing recon®rmation of candidate variants from unampli®ed DNA samples or from independently ampli®ed samples may be warranted, as is currently the case for alterations detected in PCR ampli®ed samples.
Detection of large-scale genetic alterations after whole genome ampli®cation
Methods for robust whole genome ampli®cation may enable genome-wide analysis of the somatic genetic alterations from samples that are limited to a few hundred cells. Samples where there is an obvious need for such ampli®cation include needle aspiration biopsy specimens, samples of preneoplastic lesions, circulating cancer cells and foci of cancer isolated by laser capture microdissection (LCM). Cancer genomes harbor numerous large-scale genetic alterations, including translocations, homozygous deletions, chromosomal and gene ampli®cations and regions undergoing LOH resulting from either hemizygous deletion or gene conversion. To determine whether such alterations are reproducibly detected after f29MDA, the SNP array data for six paired cancer/normal samples were analyzed for LOH and for copy number differences (e.g. ampli®cations and deletions) before and after f29MDA.
To determine the LOH concordance rate, each SNP allele found to be heterozygous in the normal and undergoing LOH (reduction to a homozygous state) in the cancer was compared in ampli®ed and unampli®ed pairs. Here, the mean pair-wise concordance rate was 99.58% and was highly consistent across all six pairs (Fig. 4A) . Regions of LOH typically encompass many such heterozygote SNPs, thus this degree of LOH concordance leads to highly reproducible LOH maps, as shown for chromosome 4 (Fig. 4B) . Recent data from our group has shown that homozygous deletion events and copy number changes are robustly detected using signal intensity measures derived from the SNP oligonucleotide probe sets (13) . We therefore compared the signal intensity for each SNP locus for the test samples to a set of normal controls. A hidden Markov model was constructed to estimate the most likely copy number for each locus in the test sample along each chromosome (11) . To determine whether homozygous deletions are likewise detected after f29MDA, we applied this method to the data from our cell lines. In unampli®ed samples, 11 homozygous deletions were detected. Eleven of 11 were also detected in the samples after f29MDA. Representative examples of homozygous deletions on chromosomes 3 and 9 are shown in Figure 4C (upper panels). The deletion at 3p15 in the HCC 38 cell line has been reported previously (18) .
To determine the concordance of copy number estimates between f29MDA and unampli®ed samples, the pair-wise Figure 4D .
To further ascertain the range of variation in genome representation, signal intensity ratios were calculated where, at each SNP position, the intensity in the unampli®ed sample was divided by either a replicate pair or by the corresponding f29MDA ampli®ed sample ( Fig. 5A and B) . In addition, the mean intensity ratio and the 25th and 75th percentile boundaries for the intensity ratios for all markers were determined and plotted separately (Fig. 5E ). The comparison of unampli®ed replicates versus f29MDA shows a slight systematic under-representation as the mean intensity ratio is <1 for the comparison of unampli®ed samples to ampli®ed samples (see Fig. 5E ). In addition, there is a clear structure within the f29MDA plots not apparent in the comparison of replicated unampli®ed samples (compare Fig. 5B and A) . The nature of this additional structure within these data is not clear, however, it appears to be topological. This structure does not appear to contribute to the overall variation as there is no difference between replicates and f29MDA ampli®ed samples with respect to the extent of overall variation (Fig. 5E ). The addition of a denaturing step prior to ampli®cation appears to have little or no effect in this structure nor was there an alteration in variation (Fig. 5C and D) .
For the purposes of estimation of relative copy number in cancer samples, standardization using f29MDA ampli®ed non-tumor samples as the copy-normal controls appears to overcome these problems. To evaluate how well copy number estimates were preserved after f29MDA, copy number estimates were binned in six categories: 0, 1, 2, 3, 4 and >4. Using these binned estimates, the copy number concordance for unampli®ed f29MDA pairs was 87%, comparable to that obtained for unampli®ed replicates. The majority of copy number discrepancies were single copy disagreements, while <1% were discrepant by more than one copy number difference (Table 3) . This allowed us to compare the detection of regions of copy number ampli®cation between f29MDA and unampli®ed samples. In this set of cell lines eight regions of high copy number ampli®cation were identi®ed in the unampli®ed cancer samples and were con®rmed by quantitative real-time PCR. All eight were also detected in f29MDA samples with comparable copy number estimates (see Table 4 ).
DISCUSSION
Large-scale sequencing, SNP genotyping and cancer genomic studies will, over the next few years, allow de®nition of the germline and somatic genetic alterations causally linked to oncogenesis. Currently, such studies require substantial quantities of high quality DNA. Indeed, a number of efforts directed at cancer somatic genetics have been initiated with cell lines because of the quantity of DNA required (19) . Techniques such as f29MDA that allow the robust ampli®-cation of entire genomes from a limited number of genome copies hold the potential to allow large-scale studies to be conducted from primary sample sources. Sources of interest include not only surgically resected specimens, but also genomes isolated from needle biopsies, buccal swabs, circulating cancer cells, LCM cells and ultimately from single tumor cells. In order for ampli®ed DNA to be utilized in high resolution genetic analysis, uniform and accurate genomewide representation are required.
Genome coverage
Here we report the ®rst genome-scale survey to determine the extent of coverage by f29MDA using high density SNP arrays. The results presented herein rely on sampling >10 000 SNP markers spaced across the genome with a mean intermarker distance of 210 kb. The 10K SNP array, however, contains no probes for markers on 13p, 14p, 15p, 21p, 22p or Y and poor representation of centromeric and telomeric regions of other chromosomes. This array representation further varies between chromosomes, being sparsest for chromosomes 17, 19, 20 and 22. The median intermarker distance, which leaves out these areas, is 105 kb. Thus, while this sampling was not perfectly distributed across the genome, it is likely that the genome coverage results reported herein can be extrapolated to these uncovered regions. In this study, PAGE 7 OF 11 call rate and allele genotype were determined for f29MDA and paired unampli®ed samples. Overall, f29MDA samples rendered call rates comparable to, but slightly lower than (although not reaching statistical signi®cance), those of unampli®ed DNA. While genome coverage was estimated to be 99.82%, we identi®ed six regions that were consistently non-represented in whole genome ampli®cation DNA. In addition, eight additional regions were under-represented. Although we obtained correct calls for SNPs in these eight regions, signal intensity was consistently lower across all samples, so this reduction in representation might impair other genetic analysis techniques, e.g. gene copy number determination. For most applications this extent of genome coverage will suf®ce, however, if speci®c susceptibility genes or susceptibility loci fall within such under-or unampli®ed regions, important genetic contributors to disease might be missed. Prior studies assessing the genome coverage of f29MDA (4,20,21) interrogated a total of 100 loci distributed across all chromosomes and noted robust coverage of these speci®c loci, though under-representation of LINE1 elements was also noted. Whether this contributes to the failure to amplify the six regions detected in our studies is not yet clear.
Application to large-scale SNP genotyping efforts
In this survey of 10 000 SNP genotypes there was high concordance between f29MDA and unampli®ed DNA. This is in keeping with previous reports on a limited number of SNPs where concordance was 100 (4, 20) and 99.7% (21) . In our study there was no statistical difference between f29MDA and unampli®ed samples in SNP call concordance. Indeed, previous data as well as our own support the notion that preservation of SNP heterozygotes after f29MDA ampli®ca-tion is quite robust. Based on our data on genome representation, if SNPs fall within regions that are poorly ampli®ed there will be a loss of detection for these SNPs. Thus, as higher density SNP maps become available, the number of indeterminate SNP calls (or`missing SNP data') may grow. The overall SNP error rate after f29MDA is within that expected from experimental error of this assay, therefore, we conclude that f29MDA DNA can be used for genome-wide SNP mapping studies. Preliminary results using f29MDA to perform similar genotyping studies on DNA obtained after LCM demonstrate call and concordance rates similar to those obtained with cell line DNA (data not shown).
Application to high throughput sequencing efforts
The ®delity of a PCR-based sequencing pipeline is constrained by the least accurate step. In our case, the limiting step is PCR ampli®cation using a proofreading-de®cient Taq polymerase. Direct sequencing of a pool of PCR products tends to minimize, although not eliminate, random errors introduced by the polymerase during PCR. Thus, the quality of initial template DNA introduced into the PCR reaction is critical. f29 polymerase has been reported to possess an intrinsic proofreading activity ensuring accurate DNA replication (6) .
To investigate the ®delity of MDA in our system, we resequenced 100 tyrosine kinase amplicons in 20 pairs of whole genome ampli®cation or unampli®ed samples.
Although, we observed virtually identical error rates (~1 Q 10 ±5 ) for both f29MDA and unampli®ed samples, we did ®nd a small excess of homozygous changes in f29MDA samples. This may be due to the fact that the resequencing study was done without the denaturing step prior to MDA. Thus, in keeping with our SNP concordance results, we hypothesize that the inclusion of a denaturation step before ampli®cation may partially correct the allele bias. The rate of error introduced by f29MDA appears to be quite low, although, nonetheless, con®rmational sequencing of candidate variants from unampli®ed DNA samples or from independently ampli®ed samples is warranted.
Application to the detection of LOH and copy number changes
Large-scale genetic alterations, including changes in gene copy number such as deletions and ampli®cation or LOH, are hallmarks of the perturbed cancer cell genome (22) . As expected from the very high SNP concordance rate, the concordance of LOH between f29MDA and unampli®ed cancer samples is also very high (99.58%), allowing the construction of robust LOH maps (23) for the study of the genetic alterations of cancer cell genomes. With respect to copy number alterations, our results indicate that MDA results in a change in the copy number structure but does not increase the mean variation in signal intensity (Fig. 5) . While this manuscript was in preparation, Lage et al. (24) reported signi®cant over-and under-representation of clusters of yeast ORFs evaluated by array-CGH. Most of the underrepresented loci map to the ends of yeast chromosomes. Similar results were obtained on human cDNA arrays. Whether these alterations are similar to those seen in our data remains to be determined. Additional studies using quantitative PCR have shown that loci representation in f29MDA DNA, as a percentage relative to an unampli®ed genomic DNA standard, ranged between 50 and 300%, a maximum 6-fold bias between any two loci (20) . Despite these changes in genome representation, for the purpose of detecting copy number changes in cancer samples we found that normalization against f29MDA non-tumor samples led to copy number estimates that were relatively well preserved after f29MDA, with a copy number concordance of 87% between f29MDA and unampli®ed samples. In addition, copy number variation was typically con®ned to within a single copy number unit and variation outside of that bound was unusual. There are three reasons that may explain high copy number concordance rates in our data despite the signal intensity variations seen here and in other studies. First, the SNP probes tend to be under-represented in telomeric and centromeric regions, where increased copy number variability was noted. Second, many of the signal intensity changes between unampli®ed and f29MDA ampli®ed samples appear to be systematic rather than random errors and are corrected by normalizing against a f29MDA ampli®ed control. This ®nding was also noted by Lage et al. in their work with MDA using the Bst polymerase (24) . Finally, signal intensity changes in individual loci do not necessarily translate into copy number errors when applying our method for determining copy number based on hidden Markov models. This method utilizes the signal intensities of neighboring loci when estimating the copy number for a given locus, therefore averaging over random errors. Importantly, cancer-associated high level ampli®cation and homozygous deletions were readily and reliably detected in f29MDA samples.
In summary, our results show that f29MDA DNA provides a highly accurate and comprehensive representation of the unampli®ed genome, suitable for high resolution genetic analysis, including SNP genotyping, gene copy number detection and direct sequencing. Thus, it is now reasonable to expect that such technologies may be widely applied on a genome scale to primary clinical samples.
